- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Roivant Sciences Receiving Interest in Bowel Disease Treatment, Bloomberg Says
Medication reportedly worth more than $7 billion.
Roivant Sciences, a biotechnology company, is reportedly garnering interest in its inflammatory bowel disease treatment from major pharmaceutical companies. Expected to be worth over $7 billion, the drug is also being tested for the treatment of ulcerative colitis and Crohn’s disease. While deliberations have focused mainly on the treatment, it’s possible the entire company could be sold as well, according to insiders, requesting not to be identified due to the matter not being public.
Presently, there is no deal in place as Roviant could elect to keep the treatment, the insiders stated.
Reference: Roivant Attracts Interest for $7 Billion-Plus Bowel Drug. Bloomberg. July 6, 2023. Accessed July 10, 2023. https://www.bloomberg.com/news/articles/2023-07-06/roivant-said-to-attract-interest-for-7-billion-plus-bowel-drug#xj4y7vzkg
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
